Evidence map›Paper›PMID 39062187›Full record

ArticleBiomedicines2024

Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves.

Konstantinos Protopapas, Konstantinos Thomas, Charalampos D Moschopoulos, Eirini Oktapoda, Eirini Marousi, Eirini Marselou, Nikiforos Stamoulis, Christos Filis, Pinelopi Kazakou, Chrysanthi Oikonomopoulou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Konstantinos Protopapas4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0001-5404-746X
Konstantinos Thomas4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0002-7489-7776
Charalampos D Moschopoulos4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0001-9954-7409
Eirini Oktapoda4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Eirini Marousi4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Eirini Marselou4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Nikiforos Stamoulis4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0009-0006-5617-2989
Christos Filis4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Pinelopi Kazakou4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Chrysanthi Oikonomopoulou4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Georgios Zampetas4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Ourania Efstratiadou4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Katerina Chavatza4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0002-1274-0909
Dimitra Kavatha4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Anastasia Antoniadou4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0003-0991-9198
Antonios Papadopoulos4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.ORCID 0000-0003-4735-2620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrently approved SARS-CoV-2 vaccines have been proven effective in protecting against severe COVID-19; however, they show variable efficacy against symptomatic infection and disease transmission. We studied the breakthrough COVID-19 infection (BTI) after booster vaccination against SARS-CoV-2 in people living with HIV (PWH).

methodsThis was a retrospective, single-center, descriptive cohort study involving PWH, who were followed in the HIV Clinic of "Attikon" University Hospital in Athens, Greece. A BTI was defined as a case of laboratory-confirmed COVID-19 occurring at least 14 days after the third (booster) vaccine dose.

resultsWe studied 733 PWH [males: 89%, mean age: 45.2 ± 11.3 years, mean BMI: 26.1 ± 4.1, HIV stage at diagnosis (CDC classification): A/B/C = 80/9/11%, MSM: 72.6%] with well-controlled HIV infection. At least one comorbidity was recorded in 54% of cases. A history of ≥1 vaccination was reported by 90%, with 75% having been vaccinated with ≥3 vaccines. Four hundred and two (55%) PWH had a history of COVID-19 and 302 (41.2%) had a BTI, with only 15 (3.7%) needing hospitalization. Only one patient was admitted to the ICU, and no death was reported. Regarding BTI after booster dose, increased age (OR = 0.97, 95% CI: 0.96-0.99, per 1-year increase), and COVID-19 infection prior to booster dose (OR = 0.38, 95% CI: 0.21-0.68) were associated with a lower likelihood for BTI, whereas higher BMI (OR = 1.04, 95% CI: 1.01-1.08) and MSM as a mode of HIV transmission were associated with increased risk (OR = 2.59, 95% CI: 1.47-4.56). The incidence rate of total COVID-19 and BTI followed the epidemic curve of the general population, with the highest incidence recorded in June 2022.

conclusionsA significant proportion of PWH with well-controlled HIV infection experienced a BTI, with the majority of them having mild infection. These data, which include the period of Omicron variant predominance, confirm the importance of vaccination in the protection against severe COVID-19.

Indexed as

booster dosebreakthrough infectionCOVID-19HIV infectionOmicron variantvaccines

Identifiers

PMID39062187
PMCPMC11274973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.